MRRS adds "Frontier Pharma: Gastric Cancer – Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients. As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.

Table of Contents
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Development Remains Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Disease Symptoms 9
4.3 Epidemiology and Etiology 9
4.4 Pathophysiology 9
4.4.1 Helicobacter Pylori 10
4.4.2 Oncogenes 10
4.4.3 Tumor Suppressor Genes 10
4.4.4 Cell Adhesion Molecules and Metastasis-Related Genes 10
4.4.5 Cell Cycle Regulators 10
4.4.6 Microsatellite and Chromosomal Instability 10
4.4.7 Growth Factor and Cytokines 11
4.5 Diagnosis and Staging 11
4.6 Classification 12
4.6.1 Intestinal Subtype 12
4.6.2 Diffuse Subtype 12
4.7 Prognosis 12
4.8 Treatment Options 13
4.8.1 Surgery 13
4.8.2 First-Line Therapy 13
4.8.3 Second-Line Therapy 16
4.9 Overview of Marketed Products in Gastric Cancer 17
4.9.1 Molecule Type and Target Analysis 17
4.9.2 Innovative Products in Gastric Cancer Market 19
4.9.3 Unmet Needs 19......

List of Tables and Figures 
Table 1: Gastric Cancer, Tumor, Node and Metastasis Staging 12
Table 2: Gastric Cancer, Key Features and Pipeline Activity of HER 3 36
Table 3: Gastric Cancer, Key Features and Pipeline Activity of ATM 38
Table 4: Gastric Cancer, Key Features and Pipeline Activity of L1CAM 39
Table 5: Frequency of Mutations in Components in Akt Proteins, by Cancer Type 41
Table 6: Gastric Cancer, Key Features and Pipeline Activity of AKT 1 42
Table 7: Gastric Cancer, Key Features and Pipeline Activity of AKT 2 42
Table 8: Gastric Cancer, Key Features and Pipeline Activity of AKT 3 43
Table 9: Gastric Cancer, Key Features and Pipeline Activity of FGFR-3 45
Table 10: Gastric Cancer, Key Features and Pipeline Activity of PDPK1 46
Table 11: List of Abbreviations 66.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/frontier-pharma-gastric-cancer-early-stage-pipeline-innovation-shows-shift-towards-targeted-mabs

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/